NCT02525679View on ClinicalTrials.gov

Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 655130 in Healthy Male Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

September 14, 2015

Primary Completion Date

May 27, 2016

Study Completion Date

May 27, 2016

Conditions
Healthy
Interventions
DRUG

BI 655130 (spesolimab)

DRUG

Placebo

Trial Locations (1)

2060

SGS Life Science Services - Clinical Research, Antwerp

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT02525679 - Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 655130 in Healthy Male Volunteers | Biotech Hunter | Biotech Hunter